RNA Polymerases For Efficient mRNA Manufacturing

The transition of mRNA therapeutics from niche breakthroughs to a core medical modality has placed unprecedented pressure on manufacturing performance. While in vitro transcription (IVT) is a well-established process, its efficiency is fundamentally tied to the behavior of the RNA polymerase. Standard bacteriophage-derived enzymes often struggle with the demands of modern, complex constructs, frequently leading to abortive transcripts and double-stranded RNA (dsRNA) byproducts.

Strategic enzyme selection during early development allows manufacturers to address these challenges at the source rather than relying on intensive downstream purification. Engineering advances now enable polymerases to maintain high yields and capping efficiency even in demanding applications like self-amplifying RNA. Prioritizing enzymatic fidelity simplifies technology transfer and ensures long-term scalability across diverse therapeutic portfolios.